Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) CEO Emil D. Kakkis Purchases 5,000 Shares
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) CEO Emil D. Kakkis bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was bought at an average price of $43.63 per share, with a total value of $218,150.00. Following the completion of the acquisition, the chief executive officer now owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
NASDAQ:RARE traded up $1.74 during midday trading on Wednesday, hitting $44.87. 63,200 shares of the company were exchanged, compared to its average volume of 474,420. The company has a current ratio of 9.32, a quick ratio of 9.14 and a debt-to-equity ratio of 0.04. Ultragenyx Pharmaceutical Inc has a fifty-two week low of $37.44 and a fifty-two week high of $90.98. The company has a market capitalization of $2.49 billion, a PE ratio of -6.12 and a beta of 2.13. The company has a fifty day simple moving average of $56.18 and a 200 day simple moving average of $61.77.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative return on equity of 49.84% and a negative net margin of 527.49%. The business had revenue of $24.15 million for the quarter, compared to analysts’ expectations of $22.16 million. During the same quarter in the previous year, the firm earned ($1.06) earnings per share. The business’s revenue was up 88.8% compared to the same quarter last year. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc will post -7.03 EPS for the current year.
Several equities research analysts have weighed in on the company. ValuEngine downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, September 5th. Leerink Swann reiterated a “positive” rating and issued a $85.00 price objective (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, September 4th. Wedbush reiterated a “buy” rating and issued a $75.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Thursday, August 15th. BidaskClub lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the stock. Ultragenyx Pharmaceutical has an average rating of “Buy” and a consensus price target of $75.64.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Article: Systematic Risk and Investors
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.